Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 273 participants.
Also called NCT04504370
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 273 participants
- Sponsor
- Registry
-
NCT04504370
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04504370. Randomized; quadruple masking; primary purpose treatment. Start 2020-04-27 (actual); primary completion 2022-03-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects
- Acronym
- PB119
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug)
- GLP-1 receptor agonist
- Intervention (Drug)
- Placebo
- Lead sponsor
- PegBio Co., Ltd.
Record details
- Record id
cardio:ct-nct04504370- Content hash
d8c4175b289411fe8edbd91d64406b5f98b597b011b93edc6b9ae1633946c38d